

DAFTAR PUSTAKA

1. Guyton A. C., Hall J. E. Guyton and Hall: Textbook of Medical Physiology 13th Edition. 2020;321–30.
2. KDIGO. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). *Kidney Int.* 2024 Apr;105(4).
3. Suwitra K. Penyakit Ginjal Kronik. Dalam : Buku Ajar Ilmu Penyakit Dalam. Edisi Ke-6. Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editors. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam; 2014. 2159–2165 p.
4. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Vol. 12, *Kidney International Supplements*. Elsevier B.V.; 2022. p. 7–11.
5. Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. *Nat Rev Nephrol.* 2024;
6. Bikbov B. Core global metrics of chronic kidney disease (CKD) mortality in the GBD 2019 Study. 2024 [cited 2024 Apr 24];
7. Curtin SC, Tejada-Vera B, Bastian BA. Deaths: Leading Causes for 2020. 2020.
8. Annual Data Report | USRDS [Internet]. [cited 2024 Apr 8]. Available from: <https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/1-ckd-in-the-general-population>
9. Badan Penelitian dan Pengembangan Kesehatan Kementerian RI. Laporan Riset Kesehatan Dasar (Riskesdas) Nasional. 2018;
10. Dinas Kesehatan Provinsi Sumatera Barat. Laporan Riset Kesehatan Dasar Sumatera Barat. 2018;
11. Laporan Rumah Sakit – RSUP. Dr. M. Djamil Padang [Internet]. [cited 2024 Apr 9]. Available from: <https://rsdjamil.co.id/laporan-rumah-sakit/>
12. Perhimpunan Nefrologi Indonesia (Pernefri). Annual Report of Indonesian Renal Registry. 2018.
13. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: A systematic review. Vol. 17, *Journal of the American Society of Nephrology*. American Society of Nephrology; 2006. p. 2034–47.
14. Gaggini M, Gorini F, Vassalle C. Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk

in Patients with Hyperlipidemia. Vol. 24, International Journal of Molecular Sciences. MDPI; 2023.

15. Ceja-Galicia ZA, Aranda-Rivera AK, Amador-Martínez I, Aparicio-Trejo OE, Tapia E, Trujillo J, et al. The Development of Dyslipidemia in Chronic Kidney Disease and Associated Cardiovascular Damage, and the Protective Effects of Curcuminoids. Vol. 12, Foods. MDPI; 2023.
16. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease Pathophysiological Insights and Therapeutic Options. Vol. 143, Circulation. Lippincott Williams and Wilkins; 2021. p. 1157–72.
17. Rosenstein K, Tannock LR. Dyslipidemia in Chronic Kidney Disease. Endotext [Internet]. 2022 Feb 10 [cited 2024 Apr 4];
18. Jacobsen AP, Whelton SP, Blumenthal RS, Mcevoy JW. Dyslipidemia. Hypertension: A Companion to Braunwald's Heart Disease [Internet]. 2023 Jul 10 [cited 2024 Apr 13];476–88.
19. Shi M, Wang H, Zhang X. Dyslipidemia and its associated factors among community adults located in Shangcheng district, Zhejiang province. Sci Rep. 2024 Dec 1;14(1).
20. Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia Associated with Chronic Kidney Disease. Vol. 5, The Open Cardiovascular Medicine Journal. 2011.
21. Kerr AG, Andersson DP, Dahlman I, Rydén M, Arner P. Adipose Insulin Resistance Associates with Dyslipidemia Independent of Liver Resistance and Involves Early Hormone Signaling. Arterioscler Thromb Vasc Biol. 2023 Jun 1;43(6):1054–65.
22. Das D, Hossale B, Purayil SK. Evaluation of Lipid Profile in Patients with Non-diabetic Chronic Kidney Disease. Assam Journal of Internal Medicine [Internet]. 2024 Jul;14(2):109–14.
23. Mikolasevic I, Žutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: Etiology and management. Vol. 10, International Journal of Nephrology and Renovascular Disease. Dove Medical Press Ltd; 2017. p. 35–45.
24. Gluba-Brzozka A, Franczyk B, Rysz J. Cholesterol disturbances and the role of proper nutrition in CKD patients. Vol. 11, Nutrients. MDPI AG; 2019.
25. Kochan Z, Szupryczynska N, Malgorzewicz S, Karbowska J. Dietary Lipids and Dyslipidemia in Chronic Kidney Disease. Nutrients [Internet]. 2021 Sep 1 [cited 2024 Apr 9];13(9).

26. Massy ZA, De Zeeuw D. LDL cholesterol in CKD—to treat or not to treat? *Kidney Int.* 2013 Sep 1;84(3):451–6.
27. Gai Z, Wang T, Visentin M, Kullak-Ublick GA, Fu X, Wang Z. Lipid accumulation and chronic kidney disease. Vol. 11, *Nutrients*. MDPI AG; 2019.
28. Valdivielso JM, Rodríguez-Puyol D, Pascual J, Barrios C, Bermúdez-López M, Sánchez-Niño MD, et al. Atherosclerosis in chronic kidney disease: More, less, or just different? Vol. 39, *Arteriosclerosis, Thrombosis, and Vascular Biology*. Lippincott Williams and Wilkins; 2019. p. 1938–66.
29. Kosugi T, Eriguchi M, Yoshida H, Tasaki H, Fukata F, Nishimoto M, et al. Association between chronic kidney disease and new-onset dyslipidemia: The Japan Specific Health Checkups (J-SHC) study. *Atherosclerosis*. 2021 Sep 1;332:24–32.
30. Liang X, Ye M, Tao M, Zheng D, Cai R, Zhu Y, et al. The association between dyslipidemia and the incidence of chronic kidney disease in the general Zhejiang population: A retrospective study. *BMC Nephrol.* 2020 Jul 2;21(1).
31. Suh SH, Kim SW. Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview. Vol. 47, *Diabetes and Metabolism Journal*. Korean Diabetes Association; 2023. p. 612–29.
32. Vaidya SR, Aeddula NR. Chronic Kidney Disease. *The Scientific Basis of Urology, Second Edition* [Internet]. 2022 Oct 24 [cited 2024 Apr 8];257–64.
33. Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. *Kidney Int.* 2024 Apr 1;105(4):684–701.
34. Supramanian K, Sekar M, Safwan N, Afendi HN. Chronic Kidney Disease: Etiology, Pathophysiology, and Management Strategies to Increase Quality of Life [Internet]. 2024.
35. Hustrini NM, Susalit E, Rotmans JI. Prevalence and risk factors for chronic kidney disease in Indonesia: An analysis of the National Basic Health Survey 2018. *J Glob Health* [Internet]. 2022 [cited 2024 Jun 21];12:4074.
36. Bruno V, Mühlhig AK, Oh J, Licht C. New insights into the immune functions of podocytes: the role of complement. Vol. 10, *Molecular and Cellular Pediatrics*. Springer Science and Business Media Deutschland GmbH; 2023.
37. Lousa I, Reis F, Beirão I, Alves R, Belo L, Santos-Silva A. New Potential Biomarkers for Chronic Kidney Disease Management-A Review of the Literature. *Int J Mol Sci* [Internet]. 2020 Jan 1 [cited 2024 Oct 15];22(1):1–37.

38. Rayego-Mateos S, Marquez-Expósito L, Rodrigues-Diez R, Sanz AB, Guiteras R, Doladé N, et al. Molecular Mechanisms of Kidney Injury and Repair. Vol. 23, International Journal of Molecular Sciences. MDPI; 2022.
39. Altamura S, Pietropaoli D, Lombardi F, Del Pinto R, Ferri C. An Overview of Chronic Kidney Disease Pathophysiology: The Impact of Gut Dysbiosis and Oral Disease. Vol. 11, Biomedicines. Multidisciplinary Digital Publishing Institute (MDPI); 2023.
40. Mishra M, Nichols L, Dave AA, Pittman EH, Cheek JP, Caroland AJV, et al. Molecular Mechanisms of Cellular Injury and Role of Toxic Heavy Metals in Chronic Kidney Disease. Vol. 23, International Journal of Molecular Sciences. MDPI; 2022.
41. Lateef Alkhaqani A. Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients Attending Al-Sadder Medical Hospital in Al-Najaf City. Turkish Journal of Physiotherapy and Rehabilitation [Internet]. 2021;32(3).
42. Effendi I, Markum HMS. Pemeriksaan Penunjang Pada Penyakit Ginjal. Dalam : Buku Ajar Ilmu Penyakit Dalam. 2014;
43. Kyneissia Gliselda V. Diagnosis dan Manajemen Penyakit Ginjal Kronis (PGK) [Internet]. 2021. Available from: <http://jurnalmedikahutama.com>
44. Farrell DR, Vassalotti JA. Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what? Vol. 25, BMC Nephrology. BioMed Central Ltd; 2024.
45. Chowdhury JZ, Alam MM, Mollah FH. Comparison of CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula based eGFR (estimated glomerular filtration rate) with C-G (Cockcroft-Gaul) and MDRD (Modification of Diet in Renal Disease) formula based eGFR in adult Bangladeshi population. Bangabandhu Sheikh Mujib Medical University Journal. 2021;14(4):152–6.
46. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. Vol. 322, JAMA - Journal of the American Medical Association. American Medical Association; 2019. p. 1294–304.
47. CKD-EPI Creatinine Equation (2021) | National Kidney Foundation [Internet]. [cited 2024 Oct 15].
48. Weir VA, Methven S. A practical guide to diagnosis and assessment of chronic kidney disease for the non-nephrologist education. Journal of the Royal College of Physicians of Edinburgh. 2020;50(1):67–74.
49. Kementerian Kesehatan Indonesia. Keputusan Menteri Kesehatan Indonesia Pedoman Nasional Pelayanan Kedokteran Tata Laksana Ginjal Kronik. 2023.

50. Alnazer I, Bourdon P, Urruty T, Falou O, Khalil M, Shahin A, et al. Recent advances in medical image processing for the evaluation of chronic kidney disease. Vol. 69, Medical Image Analysis. Elsevier B.V.; 2021.
51. Hashmi MF, Benjamin O, Lappin SL. End-Stage Renal Disease. StatPearls [Internet]. 2023 Aug 28 [cited 2024 Sep 15]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK499861/>
52. Yen CL, Fan PC, Lee CC, Chen JJ, Kuo G, Tu YR, et al. Association of Low-Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease. J Am Heart Assoc. 2022;11(19).
53. Adam JM. Dislipidemia. Dalam : Buku Ajar Ilmu Penyakit Dalam. METABOLIK. 2014.
54. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2001.
55. Aman AM, Soewondo P, Soelistijo SA, Arsana PM, Wismandari, Zufry H, et al. Panduan Pengelolaan Dislipidemia di Indonesia. 2021.
56. Natesan V, Kim SJ. Lipid metabolism, disorders and therapeutic drugs – Review. Vol. 29, Biomolecules and Therapeutics. Korean Society of Applied Pharmacology; 2021. p. 596–604.
57. Karam I. Hyperlipidemia Background and Progress [Internet]. 2017.
58. Botham KM, Mayes PA. Sintesis, Transpor, dan Ekskresi Kolesterol. Dalam : Harper's Illustrated Biochemistry 30th Edition. 2015.
59. Botham KM, Mayes PA. Pengangkutan dan Penyimpanan Lipid. Dalam : Harper's Illustrated Biochemistry 30th Edition. 2015.
60. Chandel NS. Lipid metabolism. Cold Spring Harb Perspect Biol. 2021;13(9).
61. Álvarez-López H, Ruiz-Gastélum E, Díaz-Aragón A. Conociendo los mecanismos básicos del metabolismo de los lípidos. Cardiovascular and Metabolic Science. 2021;32(S3):147–52.
62. Erwinanto, Ng S, Santoso A, Desandri DR, Erika, Renan S, et al. Panduan Tata Laksana Dislipidemia. 2022.
63. Chen X, Zhou L, Hussain MM. Lipids and Dyslipoproteinemia. Dalam : Henry's : Clinical Diagnosis and Management by Laboratory Methods 24th Edition. 2022.

64. Nordestgaard BG. A Test in Context: Lipid Profile, Fasting Versus Nonfasting. 2017.
65. Tri Widada S, Atik Martsiningsik M, Cicilia Carolina S, Kemenkes Yogyakarta Jln Ngadinengaran P. Gambaran Perbedaan Kadar Kolesterol Total Metode CHOD-PAP (Cholesterol Oxidase-Peroxisidase Aminoantipirin) Sampel Serum dan Sampel Plasma EDTA [Internet]. Vol. 5,
66. Nissa C, Pratiwi SN, Majidah S, Rahma N, Paramastuti R, Hindarta NA, et al. The Effects of Papaya Leaves Jelly in Lipid Profile Among Overweight Woman. 2020;
67. Martins J, Steyn N, Rossouw HM, Pillay TS. Best practice for LDL-cholesterol: when and how to calculate. Vol. 76, Journal of Clinical Pathology. BMJ Publishing Group; 2023. p. 145–52.
68. Rahayu C, Agriyanti A, Studi III Analisis Kesehatan PD, Kesehatan F, Mohammad Husni Thamrin U. Perbedaan Hasil Pemeriksaan LDL Direk (Metode Homogen) Dengan Indirek (Formula Friedelwald) Pada Pasien Penderita Dislipidemia di Rumah Sakit Islam Jakarta Cempaka Putih. Maret 2019 p-Open Journal System (OJS): journal.thamrin.ac.id [Internet]. 2019;5(1).
69. Kawanami D, Matoba K, Utsunomiya K. Dyslipidemia in diabetic nephropathy. Vol. 2, Renal Replacement Therapy. BioMed Central Ltd.; 2016.
70. Gai Z, Wang T, Visentin M, Kullak-Ublick GA, Fu X, Wang Z. Lipid accumulation and chronic kidney disease. Vol. 11, Nutrients. MDPI AG; 2019.
71. Sharma S, Smyth B. From proteinuria to fibrosis: An update on pathophysiology and treatment options. Vol. 46, Kidney and Blood Pressure Research. S. Karger AG; 2021. p. 411–20.
72. Yanai H. Hyperlipidemia due to Nephrotic Syndrome: Its Effects and Effects of Interventions on Atherogenesis, Cardiovascular and Renal Outcomes. J Endocrinol Metab. 2020;10(3–4):63–73.
73. Baek HS. Mechanism, clinical consequences, and management of dyslipidemia in children with nephrotic syndrome. Vol. 26, Childhood Kidney Diseases. Korean Society of Pediatric Nephrology; 2022. p. 25–30.
74. Van De Wouw J, Joles JA. Albumin is an interface between blood plasma and cell membrane, and not just a sponge. Vol. 15, Clinical Kidney Journal. Oxford University Press; 2022. p. 624–34.

75. Liu H, Peng D. Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism. Vol. 11, Endocrine Connections. BioScientifica Ltd.; 2022.
76. Castillo ZR, López ER, Noguez MM, Adame ES, Morales BH, Cortés LG, et al. Association of Dyslipidemia in Decreased Glomerular Filtration Rate in Patients with CKD KDIGO ≥ 3 . Annals of Case Reports. 2024 Apr 3;9(2).
77. Menteri Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016. Indonesia; 2016. p. 22.
78. Salsabila A, Herman H, Natasha N, Shafira A, Fauzan R, Wulandari PS. Gambaran Karakteristik Gagal Ginjal Kronik Obstruktif dan Non-obstruktif pada Pasien Dewasa-Lansia di RSUD Raden Mattaher Tahun 2017-2020. 2023.
79. Anderson AH, Xie D, Wang X, Baudier RL, Orlandi P, Appel LJ, et al. Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases. 2021 Jan 1;77(1):56-73.e1.
80. Mallappallil M, Friedman EA, Delano BG, Mcfarlane SI, Salifu MO. Chronic kidney disease in the elderly: Evaluation and management. Vol. 11, Clinical Practice. Future Medicine Ltd.; 2014. p. 525–35.
81. Maarten RN, Taal W. Epidemiology and causes of chronic kidney disease.
82. U. RK, J. S, Swamy N. Study of clinical profile of chronic kidney disease in non-diabetic patients. International Journal of Advances in Medicine. 2021 Jul 23;8(8):1113.
83. García GG, Iyengar A, Kaze F, Kierans C, Padilla-Altamira C, Luyckx VA. Sex and gender differences in chronic kidney disease and access to care around the globe. Vol. 42, Seminars in Nephrology. W.B. Saunders; 2022. p. 101–13.
84. Ahmed SB, Dumanski SM. Do Sex and Gender Matter in Kidney and Cardiovascular Disease? Vol. 78, American Journal of Kidney Diseases. W.B. Saunders; 2021. p. 177–9.
85. Farahmand M, Ramezani Tehrani F, Khalili D, Cheraghi L, Azizi F. Endogenous estrogen exposure and chronic kidney disease; a 15-year prospective cohort study. BMC Endocr Disord. 2021 Dec 1;21(1).
86. Komaroff M, Tedla F, Helzner E, Joseph MA. Antihypertensive Medications and Change in Stages of Chronic Kidney Disease. Int J Chronic Dis. 2018;2018:1–10.

87. Ramadhanti R, Helda H. Association of Hypertension and Chronic Kidney Disease in Population Aged ≥ 18 Years Old. *Molecular and Cellular Biomedical Sciences*. 2021 Nov 1;5(3):137.
88. Lai S, Pastore S, Piloni L, Mangiulli M, Esposito Y, Pierella F, et al. Chronic kidney disease and urological disorders: Systematic use of uroflowmetry in nephropathic patients. *Clin Kidney J*. 2019 Jun 1;12(3):414–9.
89. Barman Z, Hasan M, Miah R, Mou AD, Hafsa JM, Trisha A Das, et al. Association between hyperuricemia and chronic kidney disease: a cross-sectional study in Bangladeshi adults. *BMC Endocr Disord*. 2023 Dec 1;23(1).
90. Jaffe DH, Klein AB, Benis A, Flores NM, Gabay H, Morlock R, et al. Incident gout and chronic Kidney Disease: Healthcare utilization and survival. *BMC Rheumatol*. 2019;3(1).
91. Putri MSR, Hendriyono FX, Rudiansyah M. Korelasi Kadar Kolesterol Total dan Massa Lemak Pada Pasien Penyakit Ginjal Kronik yang Menjalani Hemodialisis Rutin [Internet]. 2019.
92. Praramadhan TA, Ya'kub K, Oswari LD. Perbedaan Kadar Profil Lipid Pasien Penyakit Ginjal Diabetik dan Non-diabetik yang menjalani Hemodialisis. *Majalah Kedokteran Sriwijaya*. 2017 Apr;2.
93. Sam R, Zhang L, Tuot DS, Chaudhry R. The Decrease in Serum Total Cholesterol and Low-Density Lipoprotein (LDL) Concentrations With the Initiation of Hemodialysis Despite a Concomitant Increase in Serum Albumin Concentrations. *Cureus*. 2023 Oct 18;
94. Hulwah DOZ, Widodo, Umijati S. Gambaran Faktor Risiko Dislipidemia Pada Pasien Penyakit Ginjal Kronis Dengan Terapi Hemodialisis di RSUD Dr. Soetomo Surabaya. *Jurnal Ilmiah Indonesia*. 2019 Dec;Vol.6(Special Issue No. 2).
95. Zhang H, Shi S, Zhao XJ, Wang JK, Liu ZW, Liu FQ, et al. Association between the lipid profile and renal dysfunction in the heart failure patients. *Kidney Blood Press Res*. 2019 Mar 1;44(1):52–61.
96. Patel DSH, Bhavsar DM, Parekh DA, Bhanavadiya DR. Study of Lipid profile in chronic kidney disease patients. *Journal of Medical Science And clinical Research* [Internet]. 2019 Apr 19;7(4).
97. Murmu AProfDM. Study of Lipid Profile in Non Diabetic CKD Patients. *Journal of Medical Science And clinical Research*. 2020 Mar 22;08(03).
98. Barbagallo CM, Cefalù AB, Giammanco A, Noto D, Caldarella R, Ciaccio M, et al. Lipoprotein abnormalities in chronic kidney disease and renal transplantation. *Life*. 2021 Apr 1;11(4).

99. Lee C, Park JT, Chang TI, Kang EW, Nam KH, Joo YS, et al. Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD. *Nutrition, Metabolism and Cardiovascular Diseases*. 2022 Feb 1;32(2):410–9.
100. Ganta V, Yalamanchi R, KC M, Sahu B, Raghvendar K, Anusha G, et al. A study of lipid profile in non-diabetic chronic kidney disease. *International Journal of Advances in Medicine*. 2016;965–70.
101. Retiaty F, Dany F, Ernawati F, Nurjanah N, Efriwati E, Arifin AY, et al. Dyslipidemia in Renal Dysfunction among Non-diabetic Individuals from the 2019 Indonesian Cohort Study: A Cross-Sectional Study. *Jurnal Gizi dan Pangan*. 2023 Jul 31;18(2):71–8.
102. Senge CE, Sy Moeis E, C Sugeng CE. Hubungan Kadar Lipid Serum dengan Nilai Estimasi Laju Filtrasi Glomerulus pada Penyakit Ginjal Kronik. 2017.
103. Reiss AB, Voloshyna I, De Leon J, Miyawaki N, Mattana J. Cholesterol metabolism in CKD. Vol. 66, *American Journal of Kidney Diseases*. W.B. Saunders; 2015. p. 1071–82.
104. Miao L, Min Y, Qi B, Zhu CM, Chen JH, Deng GX, et al. Causal effect between total cholesterol and HDL cholesterol as risk factors for chronic kidney disease: a mendelian randomization study. *BMC Nephrol*. 2021 Dec 1;22(1).
105. Liu HM, Hu Q, Zhang Q, Su GY, Xiao HM, Li BY, et al. Causal effects of genetically predicted cardiovascular risk factors on chronic kidney disease: A two-sample mendelian randomization study. *Front Genet*. 2019;10(MAY).
106. Zubovic SV, Kristic S, Prevljak S, Pasic IS. Chronic Kidney Disease and Lipid Disorders. *Med Arch*. 2016 Jun 1;70(3):191–2.
107. Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Vol. 18, *Reviews in Endocrine and Metabolic Disorders*. Springer New York LLC; 2017. p. 29–40.
108. Bermúdez-López M, Arroyo D, Betriu À, Masana L, Fernández E, Valdivielso JM. New perspectives on CKD-induced dyslipidemia. Vol. 21, *Expert Opinion on Therapeutic Targets*. Taylor and Francis Ltd; 2017. p. 967–76.
109. Phukan RR, Goswami RK. Unusual dyslipidemia in patients with chronic kidney diseases. *Journal of Clinical and Diagnostic Research*. 2017 Jan 1;11(1):BC01–4.

110. Hoca E, Mermer HB, Kula AC, Ahbab S, Ataoglu HE. The effects of chronic kidney disease stages on dyslipidemia, cardiovascular disease prevalence and mortality. *North Clin Istanbul*. 2025;12(1):95–102.
111. You A, Li Y, Tomlinson B, Yue L, Zhao K, Fan H, et al. Association Between Renal Dysfunction and Low HDL Cholesterol Among the Elderly in China. *Front Cardiovasc Med*. 2021;8

